StockWatch
·
MANORAMA INDUSTRIES LTD · QQ2 FY-2027 · THE CALL

Record YoY growth masks weakening Q2 momentum; capex execution key

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsMANORAMAManorama Industries Ltd17 Nov 2026 · 6 min read
Verdict

Hold

confidence 6/10

Credibility

Grade B

Hit Q2 numbers as stated; prior capex/margin targets maintained. Debottlenecking timeline slipped from committed Q3 to 'planning stage'.

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Q2 delivered strong 42% YoY revenue growth (₹459 Cr) and 52% YoY PAT (₹81 Cr), with EBITDA margin steady at 25.8%. However, sequential PAT growth slowed sharply to 2.7% (vs 52% YoY), signaling demand/margin pressure within Q2 itself. Management's shift to refusing forward guidance ('good growth' vs prior 40%+ aspiration) and delay of debottlenecking from Q3 FY27 to 'planning stage' suggest caution entering H2. Capex execution and freight cost normalization are key catalysts.

₹458.9 Cr

Revenue · +41.9% YoY

₹80.8 Cr

Reported PAT · +51.8% YoY

Expanding

Margins · vs guidance: Corroborated

Did the claims hold up?

Management's claims vs. the numbers

Q2 revenue INR459 Cr, up 41.9% YoY from INR323 Cr

MET

Delivered ₹458.9 Cr, YoY 41.9% — verbatim match

Q2 PAT INR81 Cr, grew 51.8% YoY from INR53 Cr

MET

Delivered ₹80.8 Cr, YoY 51.8% — exact match

EBITDA margin 25.8%, grew 34.4% YoY; PAT margin 17.6%

MET

Delivered OPM 25.8%, NPM 17.3% — margin levels consistent

Plant utilization ~85% on 47,500-ton capacity

MET

Corroborated by delivered margin/volume metrics; no contrary evidence

QoQ PAT growth modest due to inventory timing, freight pressure

MET

Delivered ₹80.8 Cr (Q2) vs ~₹78.6 Cr implied Q1 = 2.7% QoQ, confirms thesis

Earnings quality

What changed since the last call

Deltas vs. the prior call

Debottlenecking timeline softened

Downgrade

Prior Q1 FY27 call: Q3 FY27 target. Current: 'Under planning, will update in Q3'. Design phase ongoing; capex ₹70–75 Cr done. Effectively delayed.

Forward growth guidance now directional, not quantified

Downgrade

Prior: implicit 40%+ growth trajectory. Current: Mgmt explicitly refused to quantify FY27 growth %, stating 'good growth' only. Analyst Utkarsh pressed for 40%/30%/20%; mgmt declined, citing 'longer-term vision'.

Value-added mix (CBE + stearin) improving

Upgrade

Now 70–75% (from prior 65–70%). Targeting 70–80% going forward. Higher margin contribution per unit.

Freight cost headwind disclosed explicitly

Neutral

Q2 impact: ₹480 bps. Global logistics (Red Sea, shipping costs) driver, not raw material inflation. Mgmt expects normalization.

The Q&A

Analysts pressed hard on three fronts: (1) Raw material cost vs freight (Nitin, BoI Mutual Fund) — mgmt held firm, clarified freight driver. (2) Cocoa price linkage to CBE/stearin realization (Vanshika, Task) — mgmt deflected, saying no direct link due to different processes. (3) Forward growth quantification (Utkarsh, Eiko Quantum) — mgmt refused, defended 'long-term vision' over quarterly targets. Overall: mgmt confident but defensive on near-term details and forward numbers.

The exchanges that mattered

Cost drivers: raw material vs freight — Nitin, Bank of India Mutual Fund

Answered

Freight cost is the primary driver, not raw material itself. We import from West African regions now; shipping/logistics inflation (Red Sea, global routes) causing headwind. Largely external macro factor.

Project status & inventory drivers — Tanay Jain, Ambit Capital

Answered

Burkina Faso on track, designing & engineering phase. LATAM progressing, shipments booked gradually. Inventory shea nuts seasonal; we started importing from West Africa region. Will normalize H2.

Volume vs realization breakdown — Dipali, Jefferies

Answered

85% volume growth, 10–15% price realization. Capex to date: ₹70–75 Cr. Debottlenecking under planning for Q3 only. Design engineer in critical phase.

Cocoa price linkage to product realization — Vanshika Gupta, Task Investments

Partial

No direct linkage. CBE manufacturing is different process; raw materials/processes different from cocoa butter. Contracts renewing; prices stable in current mode. No direct impact.

Shea procurement cost YoY increase — Praveen Jayaraman, Avendus

Partial

Freight has increased. We import shea from West African countries. Price inflation impact already in books. Can share exact percentage offline with advisors.

ROCE from capex, volume growth rate — Koushik Mohan, Trinetra Asset Managers

Partial

H1 strong base; H2 to benefit from debottlenecking and ramp-up. Expect 85–90% utilization over 2–3 years. Can't quantify exact growth percentage now.

CBE/stearin contribution peak range — Tushar Khandelwal, Nexus Equity

Answered

Currently 70–75% contribution. Comfortable band 70–80%. Solvent fractionation plant under planning and engineering stage. Complex projects; will update when materialized.

FY27 capacity utilization, new capacity timeline — Nipun Sharma, VLS Finance

Answered

Existing capacity 85% currently. New capacity from Q3 FY28 starting 40–50% utilization, reaching 85–90% over 2–3 years. Gradual ramp as commissioned.

Customer demand, slowdown or deferrals — Mahima Gidwani, PhillipCapital

Answered

No slowdown currently. Capacities fully booked for next kind of year. No deferrals observed. Demands are very healthy; adding new customers from new geographies.

Fractionation mix, margin guidance — Yogeeta Rathod, Aditya Birla Capital

Answered

Fractionation 75%, others 25% of volumes. No numeric margin guidance, but 25–27% band comfortable for us. Modest quarter-to-quarter movements expected due to macro.

Sustainable growth with existing capacity — Onkar, Shree Investment

Partial

Good headroom through FY27–28. New capacity from FY28 onwards. Believe leverage will improve margin. Currently within comfortable 25–27% EBITDA band.

Capex complexity and timeline transparency — Mayur Parkeria, Scripbox Wealth Managers

Answered

Learning from first plant (15K tons), applying to second (25K). Experienced teams. Will keep updating if changes; currently on track with priorities.

Capex commissioning timeline, revenue contribution — Shrenik Mehta, IndoAlps

Partial

₹70–75 Cr invested to date. Targeting Q3–Q4 FY28 for commissioning. Will contribute gradually from Q29 onwards as capacity scales.

Inventory pickup drivers — Aditya Sharma, Shikhara Investment Management

Answered

Q4 FY26 had seasonal sal/mango inventory. Q2 FY27 includes shea nuts bought earlier from West African regions. Early procurement aligned our sourcing. Will normalize Q3–Q4.

Growth rate maintenance with new capacity — Utkarsh Somaiya, Eiko Quantum Solutions

Dodged

It is not about hitting specific percentage. It is longer-term vision. Capex, mix, fundamentals remain intact. Will update on ups and downs in business.

Guidance

Forward guidance and management's confidence

FY27 growth expected 'healthy' (not quantified)

Medium

Management explicitly refused to quantify growth %. Analyst Utkarsh asked for 40%/30%/20% targets; mgmt deflected, citing 'longer-term vision'. Prior implicit assumption was 40%+ based on FY26 trajectory; now softened to directional 'good growth'.

EBITDA margin target 25–27% maintained

High

Q2 delivered 25.8%. Mgmt expects modest quarter-to-quarter movements due to macroeconomic factors (freight costs, product mix). Band reflects stable operating performance.

FY27 capex ₹225–250 Cr tracking on schedule

High

₹70–75 Cr invested in H1; expect more in H2 FY27 and FY28. Capex projects (Burkina Faso, fractionation plants) targeting Q3 FY28 commissioning; design & engineering phases ongoing.

Risks the call surfaced

Ranked by how much they should concern a holder

Freight cost volatility

Medium

Red Sea shipping disruptions and global freight inflation driving ₹480 bps cost pressure in Q2. Externally driven factor, partially hedged via volume and price realization gains (10–15%). Structural margin impact until global logistics normalize.

Capex project execution & timeline risk

Medium

Burkina Faso refinery and fractionation plants in 'planning/engineering' stage, not committed timelines. 4,500 MTPA debottlenecking moved from Q3 FY27 (prior Q1 guidance) to 'under planning'. Further delays would compress FY28 growth targets.

Raw material sourcing concentration & geopolitical risk

Medium

Expanded sourcing from West Africa (shea nuts, butters) for specialty fats portfolio. Burkina Faso project introduces sovereign and regulatory risk (recent coups, political instability). Concentration risk in one African region for critical inputs.

Sequential demand deceleration

Medium

QoQ PAT growth slowed to 2.7% in Q2 (vs 51.8% YoY), suggesting Q1 was stronger or Q2 faced margin/volume headwinds. Contradicts bullish 'full order book' narrative from management. Potential early signal of macro slowdown in key customer markets.

New market entry execution risk

Low

LATAM facility ramp-up, West Africa sourcing expansion, new geographic customer acquisition. Scaling operations in unfamiliar markets; requires operational discipline, local partnerships, regulatory navigation.

Management

Score 7/10. Mostly transparent on challenges (freight inflation, inventory timing, project delays). Evasive on forward growth guidance; explicitly refused to quantify FY27–FY28 revenue targets despite 42% YoY growth. Defensive tone on new capex timelines and execution. Leadership reorganization (Ashish Saraf as President, Vinita as President Business Excellence) signals maturation but no crisis. Hit Q2 numbers delivered (₹459 Cr revenue, ₹81 Cr PAT) as stated in call. Capex tracking prior guidance (₹70–75 Cr done, ₹225–250 Cr FY27 target on track). Debottlenecking timeline softened from Q3 FY27 (prior call) to 'planning stage' — soft miss on prior commitment.

What to watch next
  • 1 · Q3 FY27

    Debottlenecking commissioning (4.5K MTPA), inventory normalization expected

  • 2 · Q3 FY28

    Burkina Faso refinery/fractionation plant commissioning; 3-year payback target

  • 3 · FY28–29

    New capacity ramps to 85%–90% utilization; margin uplift from operating leverage

Capex execution and freight cost normalization are key catalysts.

Informational and educational content only. Not investment advice.